Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 687 News
1 - 10of about 687 News
August 12, 2022
Bayer statement on the decision in the BASF arbitration proceedings
READ MORE
August 11, 2022
Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture
READ MORE
August 08, 2022
Not intended for U.S. and UK Media
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
READ MORE
August 04, 2022
Second quarter of 2022
Bayer: Strong growth, outlook raised
READ MORE
August 01, 2022
Bayer expands existing investment to acquire majority share in sustainable lower carbon oilseed producer CoverCress Inc.
READ MORE
July 14, 2022
Not intended for U.S. and UK Media
Bayer to sell men’s health product Nebido™ to Grünenthal
READ MORE
June 30, 2022
Not intended for U.S. and UK Media
Kerendia™ (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes
READ MORE
June 29, 2022
Not intended for U.S. and UK Media
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
READ MORE
June 28, 2022
Not intended for U.S. and UK Media
Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions
READ MORE
June 08, 2022
Bayer’s BlueRock Therapeutics establishes European site for cell therapy innovation
READ MORE
1 - 10of about 687 News
1 - 10of about 687 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases
Discover Bayer's Latest Ad-Hoc Releases
read more